Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEODOXy: Targeting Cancer Stem Cells With NEOadjuvant DOXYcycline in Patients With Early Estrogen Receptor Positive / Human Epidermal Growth Factor Receptor 2- Negative Breast Cancer. A Prospective, Multicenter, Single Arm, Open Label Phase II Trial

NCT06452394 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT06452394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06452394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEODOXy: Targeting Cancer Stem Cells With NEOadjuvant DOXYcycline in Patients With Early Estrogen Receptor Positive / Human Epidermal Growth Factor Receptor 2- Negative Breast Cancer. A Prospective, Multicenter, Single Arm, Open Label Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2025
Completion date
December 31, 2028
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer